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Summary
Marginal structural models (MSMs) with inverse probability weighting offer an approach to
estimating causal effects of treatment sequences on repeated outcome measures in the presence
of time-varying confounding and dependent censoring. However, when weights are estimated
by maximum likelihood, inverse probability weighted estimators (IPWEs) can be inefficient
and unstable in practice. We propose a joint calibration approach for inverse probability of
treatment and censoring weights to improve the efficiency and robustness of the IPWEs for
MSMs with time-varying treatments of arbitrary (i.e., binary and non-binary) distributions.
Specifically, novel calibration restrictions are derived by explicitly eliminating covariate associ-
ations with both the treatment assignment process and the censoring process after weighting
the current sample (i.e., to optimise covariate balance in finite samples). A convex minimiza-
tion procedure is developed to implement the calibration. Simulations show that IPWEs with
calibrated weights perform better than IPWEs with weights from maximum likelihood. We
apply our method to a natural history study of HIV for estimating the cumulative effect of
highly active antiretroviral therapy on CD4 cell counts over time.
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1 Introduction
1.1 Drawbacks of the maximum likelihood approach to inverse prob-
ability weighting
Marginal structural models (MSMs) (Robins, 1999b; Robins et al., 2000) estimated by inverse
probability of treatment weighting (IPTW) are widely used to quantify causal effects of treat-
ment sequences on repeated outcome measures in the presence of time-varying confounders that
are themselves affected by past treatment history (e.g., Herna´n et al. 2001; Ko et al. 2003), i.e.,
in the presence of time-varying confounding (Daniel et al., 2013). For both cross-sectional and
longitudinal settings in practice, weights for IPTW are usually obtained by fitting a paramet-
ric treatment assignment model and then plugging in the parameter estimates from maximum
likelihood. However, this maximum likelihood approach has important drawbacks.
First, inverse probability weighted estimators (IPWEs) with weights from maximum likeli-
hood can be inefficient even when the treatment assignment model is correctly specified. This
is because, weights from maximum likelihood can achieve covariate balance across treatment
groups asymptotically, but are not guaranteed to do so in finite samples, especially when there
are many covariates. The situation is analogous to randomised experiments where randomisa-
tion balances covariates asymptotically, but not necessarily in finite samples, and substantial
imbalance can arise by chance (Pocock et al., 2002; Imai et al., 2008). In randomised experi-
ments, it has been shown on numerous occasions that methods that effectively seek to improve
covariate balance, e.g., by re-randomisation, blocking, or covariate adjustment, can increase
the efficiency of treatment effect estimators (Pocock et al., 2002; Imai et al., 2008; Morgan and
Rubin, 2012). Thus IPWEs with weights that optimise covariate balance in finite samples are
likely to be more efficient than IPWEs with weights from maximum likelihood.
Second, when the treatment assignment model is misspecified, IPWEs with weights from
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maximum likelihood can be unstable and have large mean squared error (MSE), even if this
misspecification is mild (Kang and Schafer, 2007; Cole and Herna´n, 2008; Lefebvre et al., 2008).
This is because there is a mismatch between the goals of maximizing the likelihood for predicting
treatment assignment and finding weights that adequately balance covariates. With a slightly
misspecified treatment assignment model, even if the maximised likelihood of this model is
large, weighting by the resulting weights from maximum likelihood can still lead to substantial
covariate imbalance. To reduce the risk of model misspecification, data-adaptive methods (e.g.,
machine learning methods) have been used in the literature (McCaffrey et al., 2013; Gruber
et al., 2015). However, the na¨ıve use of data-adaptive methods for weight estimation would
result in an algorithm that also aims (like maximum likelihood estimation) to achieve optimal
prediction of treatment assignment, rather than to optimise covariate balance after weighting.
The second drawback of IPWEs has motivated new covariate balancing weight methods that
directly optimise covariate balance for cross-sectional settings (e.g., Graham et al., 2012; Hain-
mueller, 2012; Imai and Ratkovic, 2014; Zubizarreta, 2015; Chan et al., 2016; Fong et al., 2018).
These methods have been shown to dramatically improve the performance of IPWEs by reduc-
ing MSE under both correct and incorrect model specification. Recent theoretical investigations
by Tan (2017) reveal that the improvement brought by the covariate balancing weight methods
is because, even under model misspecification, they can reduce the relative error of propen-
sity score (i.e., conditional probability of treatment assignment given pre-treatment covariates)
estimation, i.e., the ratio of the true propensity score to its estimated value, which controls
the MSE of the IPWE. In contrast, the maximum likelihood approach works on reducing the
absolute error of propensity score estimation, but this does not necessarily reduce its relative
error. For example, when the true propensity scores are small for an area of the covariate space,
slight underestimation of these propensity scores can induce large relative error, not absolute
error, of propensity score estimation. In this paper we also show why the maximum likelihood
approach may perform poorly in terms of removing covariate imbalances asymptotically under
mild model misspecification (see details in Section 6.3 and the Supplementary Material).
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Similar to IPTW for MSMs, inverse probability of censoring weighting (IPCW) can be used
to address the selection bias due to dependent censoring that is ubiquitous in longitudinal
settings (Herna´n et al., 2001). Within the maximum likelihood framework, this is achieved
by fitting a model for the censoring process to obtain another set of time-varying weights.
The purpose of weighting the uncensored observations at a specific time point is to create a
representative sample from the original population without censoring in terms of variables that
predict the probability of censoring at that time point (e.g., covariate and outcome histories).
However, the two above-mentioned drawbacks of IPWEs also apply to the case with IPCW
(Kang and Schafer, 2007; Cole and Herna´n, 2008; Howe et al., 2011). Because in the maximum
likelihood approach, the final weights for fitting MSMs are a product of the time-varying weights
for IPTW and IPCW, these issues are likely to exacerbate when both time-varying confounding
and dependent censoring are present.
1.2 Joint calibration approach to weight estimation
In this paper we propose methodology to improve the efficiency and robustness of IPWEs when
fitting MSMs with both IPTW and IPCW. Our idea is to jointly calibrate an initial set of time-
varying weights (e.g., from maximum likelihood) for IPTW and IPCW by imposing covariate
balance restrictions simultaneously. Here we use the term ‘covariate’ generally; depending on
specific scenarios, it can refer to baseline covariates, time-varying covariates, and history of
the repeatedly measured outcome, etc. Specifically, building upon the ‘covariate association
eliminating weights’ framework proposed in Yiu and Su (2018) for cross-sectional settings, we
propose novel calibration restrictions to explicitly remove covariate associations over time with
both the treatment and censoring processes after weighting the current sample (i.e., to optimise
covariate balance for both treatment assignment and censoring in finite samples). A convex
minimization procedure is developed to implement the joint calibration, where the solution
to the restrictions for the calibrated weights is unique and asymptotically equivalent to the
initial weights if the models for estimating these initial weights are correctly specified. Thus
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our calibration procedure maintains the consistency of the IPWEs with the initial weights.
By enforcing covariate balance as characterized in chosen models for the treatment and
censoring processes, our calibrated weights can provide better adjustment for chance imbalances
of empirical covariate distributions than the maximum likelihood approach when the models for
treatment assignment and censoring are correctly specified, and can be more robust to model
misspecification since they are designed to optimise covariate balance. Moreover, our method
is applicable to time-varying treatments with arbitrary marginal distributions (e.g., ordinal,
categorical and continuous treatments over time), which could greatly promote the flexible and
reliable implementation of MSMs in practice (e.g., the effect of cumulative doses of a treatment
on longitudinal outcomes can be estimated).
1.3 Related methods
Our research fits into the literature of covariate balancing weights (e.g., Graham et al., 2012;
Hainmueller, 2012; Imai and Ratkovic, 2014; Zubizarreta, 2015; Chan et al., 2016; Fong et al.,
2018), much of which focuses on binary treatments in cross-sectional settings. An exception is
the work of Imai and Ratkovic (2015) which considers covariate balancing weights with time-
varying binary treatments for MSMs in longitudinal settings. However, our method has several
characteristics that are distinct from the method by Imai and Ratkovic (2015). First, our
method can be applied to time-varying treatments of arbitrary marginal distributions. In the
data example presented in Section 7, we focus on ordinal time-varying treatments. Second,
we deal with both time-varying confounding and dependent censoring that are common in
longitudinal settings, while Imai and Ratkovic (2015) focus on time-varying confounding. Third,
our method can be applied to both repeated outcome measures over time and an eventual
outcome at a study end within an unbalanced observation scheme (i.e., study units can be
followed up at different time points), while Imai and Ratkovic (2015) deal with an eventual
outcome in a balanced observation scheme. Fourth, our method can incorporate a variety of
stabilized weight structures that condition on baseline covariates, while it is not clear how to
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include arbitrary stabilized weight structures in the approach by Imai and Ratkovic (2015).
Last, the imposed restrictions in our method do not increase exponentially with the number of
time periods unlike in Imai and Ratkovic (2015). Along with the proposed convex minimization
procedure, this greatly facilitates the practical implementation of our method, especially when
the non-parametric bootstrap is used for making inference.
Recently, Kallus and Santacatterina (2018) also proposed a covariate balancing weight ap-
proach for binary treatments in longitudinal settings. Specifically, they use kernel smoothing
to flexibly model expectations of the potential outcome conditional on treatment and covariate
histories up to each time point in the follow-up. Then weights are estimated by minimizing an
upper bound for imbalances of time-varying variables (as characterized by conditional expecta-
tions of the potential outcome with kernels) over time plus some penalty for the variability of
the weights. Because this approach uses information from the observed outcome when modeling
conditional expectations of the potential outcome, it is distinct from the standard IPTW ap-
proach and our calibrated IPTW approach for MSMs, where only information for the treatment
process is used. In addition, the approach in Kallus and Santacatterina (2018) involves tuning
hyperparameters of the kernels and the penalisation parameter for weight estimation. It is also
not clear how to generalize their method to accommodate continuous and other non-binary
treatments over time, which is one of the main motivations for developing our method.
In the context of handling dependent censoring, Han (2016) proposed a calibrated estimation
approach for weights in IPCW. We provide a detailed discussion of his approach and compare
it with ours for IPCW in Section 4.3.
1.4 Motivating example
Our research is motivated by data from the HIV Epidemiology Research Study (HERS), a
natural history study of 1310 women with, or at high risk of, HIV infection at four sites
(Baltimore, Detroit, New York, Providence) from 1993 to 2000 (Ko et al., 2003). During
the study 12 visits were scheduled, where a variety of clinical, behavioural and sociological
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outcomes as well as self-reported information on antiretroviral therapies (ARTs) were recorded
approximately every 6 months.
We are interested in quantifying the effect of highly active antiretroviral therapy (HAART),
which contains three or more ART regimens, on the CD4 cell counts over time in the HERS.
Because the HERS was an observational study, where therapies were not randomly assigned and
varying over time, this leads to the potential for time-varying confounding between treatment
and outcome. In particular, important HIV biomarkers such as CD4 cell counts and HIV viral
load are affected by previous treatments, but also predict current treatment assignment and
subsequent outcome measures over time. Moreover, estimation of the treatment effect may be
further complicated by dependent censoring due to patient dropout, where about half of the
871 HIV-infected women at enrolment did not complete the study. In the previous analysis by
Ko et al. (2003), weights for IPTW and IPCW were estimated using maximum likelihood to fit
several MSMs and address the time-varying confounding and dependent censoring problems in
the HERS data. However, the treatment comparison used in Ko et al. (2003) was binary for the
groups with ‘HAART’ and ‘no HAART’. Because patients on ARTs other than HAART (i.e.,
less than 3 ARTs) were combined with patients not receiving any treatment, the therapeutic
effect of HAART relative to no treatment was likely to be underestimated. In this paper,
we consider the time-varying treatment as ordinal with 3 levels—‘no treatment’, ‘ART other
than HAART’ and ‘HAART’, which therefore allows more precise quantification of the effect
of HAART.
A key complication of fitting MSMs to the HERS data is the presence of many time-
invariant and time-varying covariates and their interactions, which partly reflects the treatment
guideline when the HERS was conducted (Ko et al., 2003). This not only makes it difficult to
correctly specify the treatment assignment and censoring models, but suggests that even if this
is achieved, IPWEs with weights from maximum likelihood might be inefficient because such
weights are unlikely to adequately adjust for chance imbalances of the multivariate covariate
distribution. These concerns motivated us to develop more efficient and robust estimators for
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parameters in MSMs.
2 Notation, setting and assumptions
In this section, we introduce the notation and assumptions, and for clearer exposition, we
describe the setting of interest in the context of the HERS data.
2.1 Notation and setting
In the HERS, the treatment information was self-reported to record the ART use in the last six
months prior to the scheduled study visit. Therefore, at visit j (j = 0, 1, . . . , T ), we observe, in
chronological order, the treatment assignment Aij, a vector of time-varying covariates Xij (e.g.,
HIV viral load, HIV symptoms), and the longitudinal outcome Yij (i.e., CD4 count) from the
ith patient (i = 1, . . . , n). Note that j = 0 corresponds to baseline and we allow Aij to be of
arbitrary distribution with a possible value a. In addition, we observe Vi, a vector of baseline
covariates such as demographical variables. In this setting, we assume the temporal ordering
where Yij, Xij and Aij can only be affected by {Aij, X ij, Y i,j−1,Vi}, {Aij, X i,j−1, Y i,j−1,Vi}
and {Ai,j−1, X i,j−1, Y i,j−1,Vi}, respectively, for j = 1, . . . , T . Here an overbar represents the
history of a process, for example, X ij = {Xi1, . . . ,Xij}.
As mentioned in Section 1.4, we treat Aij, the ART use in the previous six months prior to
visit j for the ith patient, as an ordinal treatment variable. Specifically, we use two indicator
variables A0ij and A
1
ij to represent Aij, where A
0
ij is the indicator of whether at least one ART
was administered, and A1ij is the indicator of whether HAART was administered given that at
least one ART was administered (A0ij = 1). In particular, ‘no ART’, ‘one or two ARTs’ and
‘HAART’ are represented by (0, 0), (1, 0) and (1, 1), respectively. We assume that Aij depends
on treatment history Ai,j−1, history of time-varying covariates X i,j−1, history of longitudinal
outcome Y i,j−1 up to visit j−1 as well as baseline covariates Vi. This relationship is determined
by how the ART information was collected in the HERS. For other scenarios, appropriate
dependence structure in the treatment process can be specified to reflect the specific contexts;
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and our method described below can be easily adapted. For ease of exposition, we absorb
Y i,j−1, Ai,j−1 and Vi into the covariate history X i,j−1 (j = 1, . . . , T ), unless stated otherwise.
Let Y
aj
ij be the potential outcome that would have arisen at visit j had the ith patient
been assigned the potential treatment sequence aj from the first visit after baseline up to
visit j. We assume a general MSM of the form E(Y
aj
ij ) = µ(aj,γ) = g{h(aj),γ}, where
h(·) is a known function satisfying h(aj = 0) = 0, 0 is the vector of zeros, aj = 0 is the
potential treatment sequence where no treatment is administered at every visit up to visit j,
and g(·) is a known function that relates the mean of the potential outcome to h(aj) through
a finite-dimensional parameter vector γ. For example, for the HERS data we may specify
g{h(aj),γ} = γ0j + γ1
∑j
t=1(a
0
t − a1t ) + γ2
∑j
t=1 a
1
t , where a
0
t and a
1
t are potential values of
treatment indicators A0it and A
1
it, and γ1 and γ2 are the causal effects on Y
aj
ij per unit increase
of cumulative exposures to one or two ARTs and HAART, respectively.
2.2 Assumptions
In order to identify γ, MSMs rely on the sequential ignorability of treatment assignment as-
sumption, i.e., pr(Aij | Y ajij , X i,j−1) = pr(Aij | X i,j−1) for j = 1, . . . , T , also known as the
assumption of no unmeasured confounders (at each visit/time period). In addition, we make
the positivity assumption, i.e., pr(Aij ∈ A | X i,j−1) > 0 for all X i,j−1 and for any set A with
positive measure. Finally, we make the stable unit treatment value (SUTVA) assumption: the
potential outcomes are well defined; the distribution of potential outcomes for one patient is
assumed to be independent of potential treatment sequence of another patient.
In the presence of dependent censoring, the objective of MSMs is to estimate the causal
effect of the treatment sequence in the absence of censoring. Let Rij be the indicator of whether
the ith patient remains in the study up to visit j. We assume that Ri0 = 1 (i.e., baseline visit
assessments are complete for all patients) and Ri,j−1 = 0 ⇒ Rij = 0 (monotone missingness
due to dropout). Our interest is to estimate the parameters of the MSM for E(Y
aj ,rj=1
ij ), where
rj is the potential sequence of the indicator of the ith patient being in the study by visit j
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and 1 is the vector of ones. To achieve this, we make an assumption that the censoring is
sequentially ignorable, i.e., censoring at visit j depends only on observable history up to but
not including visit j. Let H ij denote this observable history, which may include X i,j−1, Ai,j−1,
Y i,j−1 and any other relevant covariate information. The sequential ignorability assumption of
censoring means that pr(Rij | Y ajij , H ij, Ri,j−1 = 1) = pr(Rij | H ij, Ri,j−1 = 1) for j = 1, . . . , T .
In addition, we assume that pr(Rij | H ij, Ri,j−1 = 1) > 0 for all H ij, which is similar to the
positivity assumption made for the treatment process.
Throughout the paper, we make the above assumptions; otherwise our method may result
in severely biased estimates for parameters in the MSM, possibly even compared to an analysis
without addressing time-varying confounding and dependent censoring.
3 Inverse probability of treatment weighting
We first focus on the IPTW approach for dealing with time-varying confounding in MSMs. The
IPCW approach for dependent censoring will be described in Section 4.
3.1 Maximum likelihood estimation
To consistently estimate γ, the following estimating equations
n∑
i=1
T∑
j=1
SWAijD(Aij,γ)
{
Yij − µ(Aij,γ)
}
= 0 (1)
can be solved, where SWAij =
∏j
k=1 pr(Aik | Ai,k−1)/
∏j
k=1 pr(Aik | X i,k−1) are the stabilized
inverse probability of treatment weights (SIPTW), D(Aij,γ) = {∂µ(Aij,γ)/∂γ}V −1ij and Vij =
var(Yij) (Robins, 1999b; Herna´n et al., 2001; Ko et al., 2003). Note that baseline covariates Vi
can also be included in the numerator of SWAij if they are included in the MSM. For simplicity,
we do not consider this here, but our method described below easily extends to this scenario.
The intuitive idea behind weighting the ith patient’s data at visit j by SWAij is to create a
pseudo-population where Aij does not depend on X i,j−1 conditional on Ai,j−1, and the causal
effect of aj on E(Y
aj
ij ) is the same as in the original population. Under the sequential ignorablity,
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positivity and SUTVA assumptions described in Section 2, the treatment process up to visit
j after weighting by SWAij will then be causally exogenous (Robins, 1999b), i.e., pr
∗(Aij |
Y
aj
ij , X i,j−1) = pr
∗(Aij | X i,j−1) = pr(Aij | Ai,j−1), where ∗ denotes the pseudo-population
after weighting by SWAij . Therefore, standard regression methods can be used to consistently
estimate the parameter γ in the specified MSM if the SIPTW are known.
Because SIPTW are unknown in observational studies, estimates of the SIPTW based on
maximum likelihood, SWAij (αˆ, βˆ) =
∏j
k=1 pr(Aik | Ai,k−1; αˆ)/
∏j
k=1 pr(Aik | X i,k−1; βˆ) are used
to implement IPTW, where αˆ and βˆ are the maximum likelihood estimates of α and β in
parametric models pr(Aij | Ai,j−1;α) and pr(Aij | X i,j−1;β).
3.2 Calibrated estimation
IPTW exploits the fact that
∏j
k=1 pr
∗(Aik | X i,k−1) =
∏j
k=1 pr(Aik | Ai,k−1) for all j. However,
due to sample randomness, weighting by SWAij (αˆ, βˆ) may not remove the associations between
Aik and X i,k−1 conditional on Ai,k−1 for k = 1, . . . , j in finite samples, even if the assumptions
in Section 2 are satisfied, and the model pr(Aik | X i,k−1;β) is correctly specified, i.e., there
exists a vector βtrue such that pr(Aik | X i,k−1;βtrue) = pr(Aik | X i,k−1). In other words, there
remain chance imbalances and residual confounding of covariates after weighting by SWAij (αˆ, βˆ),
which lead to finite sample estimation errors (Imai et al., 2008). When pr(Aik | X i,k−1;β) is
misspecified, weighting by SWAij (αˆ, βˆ) may not even guarantee that the associations between
treatment assignment and covariates are reduced after weighting relative to the observed data
(see the Supplementary Material for more details).
To overcome these problems, our key idea is to calibrate SWAij (αˆ, βˆ) by imposing restric-
tions implying that treatment assignments are unassociated with the history of time-varying
covariates over time after weighting the current sample. Specifically, the calibrated weight takes
a multiplicative form, SWA?ij (λ) = SW
A
ij (αˆ, βˆ)c(X ij,λ), where c(X ij,λ) is a non-negative func-
tion with c(X ij,λ = 0) = 1 and λ is a vector of parameters to be estimated. After obtaining
λˆ, the estimate of λ in the calibration procedure (see Section 5.2), we then replace SWAij by
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SWA?ij (λˆ) in (1) to estimate γ.
We derive calibration restrictions for SIPTW in MSMs by building on the framework pro-
posed in Yiu and Su (2018) for the cross-sectional setting. Let pr(Aij | X i,j−1;βw) be a
parametric model for the treatment assignment. Here we use the subscript ‘w’ in βw to em-
phasize that the parametric model used to derive restrictions does not have to be the same
as the one used to construct the initial weights SWAij (αˆ, βˆ), see Section 5.3 for more details.
Following Yiu and Su (2018), we use the partition βw = {βwb,βwd}, where βwd are the unique
parameters that characterize the dependence of Aij on X i,j−1 excluding the treatment history
Ai,j−1 (e.g., regression coefficients of time-varying confounders), and βwb include the intercept
terms and parameters that characterize the dependence on treatment history (e.g., regression
coefficients of Ai,j−1). Here the subscripts ‘d’ and ‘b’ stand for dependence and baseline, respec-
tively. Without loss of generality, let pr(Aij | X i,j−1;βwb = α,βwd = 0) = pr(Aij | Ai,j−1;α),
i.e., setting {βwb = α,βwd = 0} results in a treatment process model that only depends on
treatment history and is parameterized by α.
Now suppose that λ is fixed and we have known weights SWA?ij (λ), it is possible to check
whether βwd = 0 in the pseudo-population over time after weighting the current sample with
SWA?ij (λ), by finding the value of βw that maximizes
T∏
j=1
n∏
i=1
{
j∏
k=1
pr(Aik | X i,k−1;βw)
}SWA?ij (λ)
, (2)
or solves the score equations
T∑
j=1
n∑
i=1
SWA?ij (λ)
j∑
k=1
∂
∂βw
log{pr(Aik | X i,k−1;βw)} = 0. (3)
The terms in the first product in (2) makes it explicit that we would like to use SWA?ij (λ) to
weight the likelihood of the observed treatment sequence for the ith patient up to visit j. (2)
is then constructed by aggregating these terms over all patients and visits for which we require
weights SWA?ij (λ).
We propose to derive calibration restrictions by inverting (3), so that we are finding the
12
value of λ implying that {βwb = αˆ,βwd = 0} are the values that maximize (2). That is, we
solve for λ
T∑
j=1
n∑
i=1
SWA?ij (λ)
j∑
k=1
∂
∂βw
log{pr(Aik | X i,k−1;βw)}
∣∣∣{βwb=αˆ,βwd=0} = 0. (4)
Satisfaction of the restrictions in (4) means that after weighting by SWA?ij (λˆ) the treatment
assignments up to visit j are unassociated with the histories of the time-varying covariates
conditional on the treatment histories in the current sample (i.e., βwd = 0). Note that the
structure of the covariate associations is characterized by the specified parametric treatment
process model. More discussion about this general framework for weight estimation in cross-
sectional settings can be found in Yiu and Su (2018).
Another property of the true SIPTW is E(SWAij ) = 1 for j = 1, . . . , T , where the expectation
is taken with respect to {Aij, X i,j−1, Y i,j−1,Vi} (Cole and Herna´n, 2008). However, in practice
the average of the estimated weights by maximum likelihood SWAij (αˆ, βˆ) at each visit can take
values very different from one, particularly if the treatment process model is badly misspecified.
In order to help stabilize the weights, we propose to further impose the restrictions
1
n
n∑
i=1
SWA?ij (λ) = 1 (5)
for j = 1, . . . , T , in the same spirit as in Cao et al. (2009). That is, we constrain the average
of the weights to be one at each visit. The restriction in (5) also prevents the trivial solution
of zeros for the weights in (4) when only IPTW is applied (see Section 5.1 for more details).
For the setting with an eventual outcome at visit T (e.g., the CD4 count at the study end
of the HERS), restrictions can be derived by using the above procedure. However, since in this
case we would only be interested in calibrating SWAiT (αˆ, βˆ), (2) will only contain the terms
weighted by SWA?iT (λ), i.e., the terms where j = T in (2). This results in the restrictions
n∑
i=1
SWA?iT (λ)
T∑
k=1
∂
∂βw
log{pr(Aik | X i,k−1;βw)}
∣∣∣{βwb=αˆ,βwd=0} = 0 and 1n
n∑
i=1
SWA?iT (λ) = 1.
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3.3 Application to time-varying ordinal treatment
We consider the following model for the ordinal treatment variable in the HERS data,
logit {pr(A0ij = 1 | X i,j−1)} = X˜0>i,j−1β0,
logit {pr(A1ij = 1 | X i,j−1, A0ij = 1)} = X˜1>i,j−1β1,
(6)
where X˜0i,j−1 and X˜
1
i,j−1 include 1 and functionals of X i,j−1 (e.g., transformations and in-
teractions), and β0 and β1 are corresponding regression coefficients. Following Section 3.2,
restrictions based on (6) can be derived:
T∑
j=1
n∑
i=1
SWA?ij (λ)
j∑
k=1
(
A0ik − eˆ0ik
)
X˜0i,k−1 = 0,
T∑
j=1
n∑
i=1
SWA?ij (λ)
j∑
k=1
A0ik
(
A1ik − eˆ1ik
)
X˜1i,k−1 = 0,
(7)
where eˆ0ik and eˆ
1
ik are the predicted probabilities of receiving treatment at visit k from fitting
the model (6) but with treatment history as the only covariates. The restrictions in (7) are in
spirit similar to the covariate balancing restrictions/conditions for binary treatments in cross-
sectional settings (Imai and Ratkovic, 2014; Yiu and Su, 2018), but they are aggregated over
time. Examining these restrictions carefully, we can see that they aim to remove the associations
of the covariates, X˜0i,j−1 and X˜
1
i,j−1, with the residuals of the treatment variables (after fitting (6)
with treatment history as the only covariates) in the pseudo-population over time. Without the
general framework described in Section 3.2, it is not obvious how to generalize the restrictions
in cross-sectional settings (e.g., in Imai and Ratkovic (2014)) to longitudinal settings and to
arbitrary treatment distributions.
As a further example, we derive restrictions for treatment sequences with continuous marginal
distributions in the Supplementary Material.
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4 Inverse probability of censoring weighting
4.1 Maximum likelihood estimation
Recall that in the presence of censoring, our interest is to estimate the parameters of the
MSM for E(Y
aj ,rj=1
ij ). If Rij only depends on the treatment history Ai,j−1 and the MSM for
E(Y
aj ,rj=1
ij ) is correctly specified, we can still consistently estimate the parameters in this new
MSM with IPTW, but the summands in (1) are multiplied by Rij. In the calibration approach,
we would replace SWA?ij (λ) with RijSW
A?
ij (λ) in (4) and alter the scaling in (5) so that the
average of the weights is still fixed at one for each visit (i.e., replace n by
∑n
i=1Rij at visit j).
In the presence of dependent censoring, where Rij also depends on X i,j−1 including the
outcome history Y i,j−1, conditioning on uncensored observations for analysis will induce selec-
tion bias when estimating the parameters in the MSM because pr(Xi,k−1 | Ai,k−1, Rij = 1) 6=
pr(Xi,k−1 | Ai,k−1) (k = 1, . . . , j). For example, in the HERS the probability of dropout at the
current visit might depend on most recent changes in the CD4 count outcome (Ko et al., 2003).
Under the sequential ignorability and positivity assumptions for censoring described in Sec-
tion 2.2, we can apply inverse probability of treatment and censoring weighting (IPTCW) and
replace the weights in (1) by RijSW
A
ijW
C
ij , where W
C
ij =
∏j
k=1 1/pr(Rik = 1 | H i,k−1, Ri,k−1 = 1)
(j = 1, . . . , T ) are the inverse probability of censoring weights. WCij are typically estimated by
maximum likelihood after specifying a parametric model pr(Rik = 1 | H i,k−1, Ri,k−1 = 1;θ);
and WCij (θˆ) =
∏j
k=1 1/pr(Rik = 1 | H i,k−1, Ri,k−1 = 1; θˆ), where θˆ are maximum likelihood
estimates of θ.
Similarly to IPTW, stabilized weights for censoring, SWCij (ηˆ, θˆ) = W
C
ij (θˆ)
∏j
k=1 pi
s
ik(ηˆ),
can be used, where pisik(η) = pr(Rik = 1 | Ai,k−1, Ri,k−1 = 1;η) is a parametric model for
the censoring process given the treatment history only. In the next section, we describe our
proposed method for calibrating unstabilized weights for censoring; details about calibrating
stabilized weights for censoring can be found in the Supplementary Material.
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4.2 Calibrated estimation
4.2.1 The two time period setting
We consider the two time period setting (including baseline, i.e., T = 1) to convey the idea
as to how the censoring weights WCij (θˆ) can be calibrated by covariate balancing. Since Ri0 =
1 (i = 1, . . . , n), the censoring only occurs at the first follow-up visit in the two time period
setting. The aim of weighting the complete cases (those with Ri1 = 1) by 1/pii1, where pii1 =
pr(Ri1 = 1 | H i0) is the true probability of remaining in the study at the first follow-up visit, is
to create a representative sample of the target population (i.e., the population that would have
been observed in the absence of censoring) in terms of the covariates H i0. Specifically, if the
complete cases receive a weight of one to represent themselves, the additional weights 1/pii1−1
given to the complete cases are used to create a representative sample of the incomplete cases
(those with Ri1 = 0). As a result, the total
∑n
i=1 1/pii1 copies of the complete cases form the
pseudo-population after weighting, which can represent the target population.
Let ∗ denote the pseudo-population after weighting only the complete cases by 1/pii1 − 1.
IPCW exploits the fact that pr∗(Ri1 = 1 | H i0) = 1/2 = 1−pr∗(Ri1 = 1 | H i0) (see the proof in
the Supplementary Material). However, in finite samples, due to sample randomness, weighting
the complete cases by WCi1 (θˆ) − 1 will not necessarily represent the incomplete cases in terms
of covariate distributions. This motivates our calibration approach for the weights in IPCW.
Using the multiplicative form as in Section 3.2, we can write the calibrated weights as
WC?i1 (λ) = W
C
i1 (θˆ)c(H i0,λ), where c(H i0,λ) is a non-negative function satisfying c(H i0,λ =
0) = 1, and λ is the parameter vector to be estimated for the calibration. Let pii1(θw) =
pr(Ri1 = 1 | H i0;θw) be a parametric model for the censoring process with a parameter vector
θw. Now fixing λ and weighting the complete cases with the known weights W
C?
i1 (λ) − 1
to represent the incomplete cases, we can construct the likelihood for the pseudo-population
excluding the copies of themselves for the complete cases as
n∏
i=1
pii1(θw)
Ri1{WC?i1 (λ)−1} {1− pii1(θw)}1−Ri1 .
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The corresponding score equations are
n∑
i=1
Ri1
{
WC?i1 (λ)− 1
} ∂
∂θw
log{pii1(θw)}+ (1−Ri1) ∂
∂θw
log{1− pii1(θw)} = 0. (8)
Solving (8) in terms of θw provides a measure of how the additional W
C?
i1 (λ) − 1 copies of
complete cases differ from the incomplete cases. In particular, without loss of generality, let
pii1(θw = 0) = 1/2. Then if a solution to (8) is θˆw = 0, this would suggest that the W
C?
i1 (λ)−1
copies of complete cases are representative of the incomplete cases in terms of H i0, while
deviations from zero suggest otherwise. We propose to derive the restrictions for calibration by
finding λ such that θw = 0 are the values that solve (8). That is, we solve for λ such that
n∑
i=1
Ri1
{
WC?i1 (λ)− 1
} ∂
∂θw
log{pii1(θw)}+ (1−Ri1) ∂
∂θw
log{1− pii1(θw)}
∣∣∣
θw=0
= 0. (9)
For example, with a logistic model logit {pii1(θw)} = H˜>i0θw, where H˜i0 is a vector of functionals
of H i0 including 1, the restrictions based on (9) are
∑n
i=1{Ri1WC?i1 (λ)− 1}H˜i0 = 0
≡∑ni=1Ri1WC?i1 (λ)H˜i0 = ∑ni=1 H˜i0. (10)
These restrictions constrain the sample size after weighting to be n (since H˜i0 includes 1) and
the weighted averages of other elements of H˜i0 to be equal to their averages in the observed data.
Although motivated differently, these restrictions have been considered for weight estimation
(e.g., Robins et al. 2007; Vansteelandt et al. 2012; Zubizarreta 2015, among others).
4.2.2 The general longitudinal setting
The purpose of weighting the complete cases at visit j (those with Rij = 1) is to create a
representative sample of the target population (in the absence of censoring) at visit j. Let
piik = pr(Rik = 1 | H i,k−1, Ri,k−1 = 1) be the true conditional probability of remaining in the
study at visit k given the covariate history H i,k−1 and that the patient is still under follow-up
at visit k− 1 (k = 1, . . . , j). We can show by induction that the weights WCij = 1/
∏j
k=1 piik can
be used to achieve this purpose. Specifically, we know from Section 4.2.1 that weighting the
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complete cases at the first follow-up visit by WCi1 will create a representative sample of the target
population when j = 1, so the base case holds. Now we assume that the proposition holds at
visit k − 1, i.e., weighting the complete cases at visit k − 1 by WCi,k−1 creates a representative
sample of the target population at visit k − 1; and we treat this weighted population at visit
k− 1 as our new population. The inductive step at visit k requires showing that weighting the
complete cases of this new population at visit k by 1/piik will create a representative sample of
this new population if no censoring occurs. Using the same logic in Section 4.2.1, it is easy to
show that this inductive step holds for the true weight 1/piik. By the proposition at visit k− 1,
we will then have a representative sample of the target population at visit k by weighting with
WCik .
We derive calibration restrictions by following the same strategy as in Section 4.2.1. First, we
fix λ so that we have known weights WC?i1 (λ), . . . ,W
C?
ij (λ), where W
C?
ik (λ) = W
C
ik (θˆ)c(H i,k−1,λ)
and c(H i,k−1,λ) is a non-negative function satisfying c(H i,k−1,λ = 0) = 1 for k = 1, . . . , j.
We can check the validity of the proposition at visit j by specifying a parametric model
piik(θw) = pr(Rik = 1 | H i,k−1, Ri,k−1 = 1;θw) (k = 1, . . . , j) and estimating its parameter
θw by maximizing
n∏
i=1
j∏
k=1
[
piik(θw)
Rik{1/pi?ik(λ)−1} {1− piik(θw)}1−Rik
]WC?i,k−1(λ)Ri,k−1
, (11)
where 1/pi?ik(λ) = W
C?
ik (λ)/W
C?
i,k−1(λ) (k = 1, . . . , j), W
C?
i0 (λ) = 1 and by convention 0
0 = 1.
The terms in (11) are used to check the validity of the inductive steps at times k = 1, . . . , j
assuming the proposition holds at visit k − 1. In particular, deviations from θw = 0 provides
evidence against the inductive step at one or more visits up to and including visit j, and thus
evidence against the proposition at visit j. Similarly, we can simultaneously check the validity
of the proposition at each visit by maximizing
T∏
j=1
n∏
i=1
j∏
k=1
[
piik(θw)
Rik{1/pi?ik(λ)−1} {1− piik(θw)}1−Rik
]WC?i,k−1(λ)Ri,k−1
, (12)
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which is obtained by aggregating (11) across j = 1, . . . , T . We can further simplify (12) to
T∏
j=1
n∏
i=1
[
piij(θw)
Rij{1/pi?ij(λ)−1} {1− piij(θw)}1−Rij
](T−j+1)WC?i,j−1(λ)Ri,j−1
(13)
with the score equations
T∑
j=1
n∑
i=1
(T − j + 1)
[
Rij
{
WC?ij (λ)−WC?i,j−1(λ)
} ∂
∂θw
log {piij(θw)}
+ WC?i,j−1(λ)(Ri,j−1 −Rij)
∂
∂θw
log{1− piij(θw)}
]
= 0.
(14)
The inductive steps in (13) are weighted by T − j + 1 to reflect that they are required for
checking T − j + 1 propositions, specifically if the proposition holds at visits j, . . . , T . We
derive restrictions by finding λ such that θw = 0 are the values that solve (14). That is, we
solve for λ such that
T∑
j=1
n∑
i=1
(T − j + 1)
[
Rij
{
WC?ij (λ)−WC?i,j−1(λ)
} ∂
∂θw
log {piij(θw)}
+ WC?i,j−1(λ)(Ri,j−1 −Rij)
∂
∂θw
log{1− piij(θw)}
] ∣∣∣
θw=0
= 0.
(15)
In this paper we assume a logistic model logit {piij(θw)} = H˜>i,j−1θw, where H˜i,j−1 is a vector
of functionals of H i,j−1 including 1. The restrictions based on (15) are
T∑
j=1
(T − j + 1)
n∑
i=1
[
RijW
C?
ij (λ)−Ri,j−1WC?i,j−1(λ)
]
H˜i,j−1 = 0. (16)
The term
∑n
i=1
[
RijW
C?
ij (λ)−Ri,j−1WC?i,j−1(λ)
]
H˜i,j−1 in (16) can be interpreted as the balance
summary of H˜i,j−1 between the weighted complete cases at visit j and the weighted complete
cases at visit j − 1.
The restrictions in (16) are equivalent to
T∑
j=1
n∑
i=1
RijW
C?
ij (λ)
{
(T − j + 1)H˜i,j−1 − (T − j)H˜ij
}
= T
n∑
i=1
H˜i0; (17)
details can be found in the Supplementary Material. Since H˜i,j−1 (j = 1, . . . , T ) includes 1,
then (17) imposes
T∑
j=1
n∑
i=1
RijW
C?
ij (λ) = nT,
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which means that the total number of ‘observations’ after weighting is equal to nT , the total
number of observations of the target population if no censoring occurs at all. If H˜i,j−1 includes
baseline covariates Vi, (17) imposes
T∑
j=1
n∑
i=1
RijW
C?
ij (λ)Vi = T
n∑
i=1
Vi,
i.e., the weighted average of Vi over all visits is equal to the sample average of Vi. If H˜i,j−1
includes an indicator for visit, I(j = k) (k = 1, . . . , T ), and an interaction between this visit
indicator and Vi, I(j = k)Vi, then (17) imposes
n∑
i=1
RikW
C?
ik (λ) = n,
n∑
i=1
RikW
C?
ik (λ)Vi =
n∑
i=1
Vi
for k = 1, . . . , T , i.e., at each visit the sample size after weighting is n and the weighted average
of Vi is equal to the sample average of Vi.
4.3 Related work
In related work, Han (2016) proposed to calibrate inverse probability of censoring weights by
imposing similar restrictions to (16). However, the focus of Han (2016) was on an eventual
outcome at the end of study, YiT . For comparison, we derive restrictions for his target of
inference E(YiT ) as
T∑
j=1
n∑
i=1
[RijW
C?
ij (λ)−Ri,j−1WC?i,j−1(λ)]H˜i,j−1 = 0, (18)
which are based on (11) but with T as the upper limit of the product in k. If H˜i,j−1 includes
baseline covariates Vi, these restrictions impose
n∑
i=1
RiTW
C?
iT (λ) = n and
n∑
i=1
RiTW
C?
iT (λ)Vi =
n∑
i=1
Vi,
i.e., at visit T the sample size after weighting is n and the weighted average of Vi is equal to
the sample average of Vi.
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The restrictions in (18) and those in Han (2016) differ in the way they achieve parsimony,
which helps prevent unstable weights. In particular, Han (2016) imposes separate restrictions
at each visit, by multiplying the summands in (18) by the visit indicator I(j = k) (k =
1, . . . , T ). This is feasible with few follow-up visits, e.g., the simulation study in Han (2016)
has three visits. Our approach leaves the degree of smoothing over time at the discretion of
the researcher. For example, natural cubic splines can be incorporated to reflect non-linear
time trend in the censoring process, similarly to the approach in Herna´n et al. (2001) for
approximating the time-varying baseline treatment assignment distribution. Han also uses
multiple estimates of E(YiT |H i,j−1) based on different working models in place of H˜i,j−1 in
(18). Including more estimates of E(YiT |H i,j−1) in the restrictions generally lead to an increase
in efficiency when all working models are misspecified (Han, 2016). In this regard, Han’s
approach is more parsimonious than ours because his restrictions are contained in (18) if his
working models for E(YiT |H i,j−1) are linear in H˜i,j−1 (see Section 5.3 for more details).
5 Joint calibrated estimation
5.1 Combining calibrated weights
When both IPTW and IPCW are required for fitting MSMs, we propose to perform calibration
jointly and the calibrated weights are WAC?ij (λˆ) = SW
A
ij (αˆ, βˆ)W
C
ij (θˆ)c(X i,j−1, H i,j−1, λˆ), where
c(X i,j−1, H i,j−1,λ) is a non-negative function satisfying c(X i,j−1, H i,j−1,λ = 0) = 1, and λˆ is
the estimate of λ such that WAC?ij (λˆ) satisfies the restrictions (4) and (17). Since (17) already
imposes constraints on the sample size at each visit after weighting, (5) is excluded to avoid
collinearity.
Another approach is to use the product of the individually calibrated weights WAC?ij (λˆ) =
SWA?ij (λˆ)W
C?
ij (λˆ). However, while SW
A?
ij (λˆ) andW
C?
ij (λˆ) satisfy the restrictions (4)–(5) and (17)
respectively, their observation-specific product may not. Thus these estimated weights may lose
the potential benefits from calibration.
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5.2 Implementation of the calibration procedure
We collect all initial and calibrated weights into m × 1 vectors W (αˆ, βˆ, θˆ) and W ?(λ), re-
spectively, where m is the number of weights. If no censoring occurs, then m = nT . The
implementation of the joint calibration requires solving a system of linear equations in terms of
W ?(λ) since the restrictions (4)–(5) and (17) are linear in the calibrated weights. Let K be the
known m×r matrix and l be the known r×1 vector, where r is the numbers of restrictions. For
example, for IPTCW r would be the combined size of βw and θw. Both K and l are determined
by the calibration restrictions. Broadly, for obtaining the calibrated weights, we would like to
solve
K>W ?(λ)− l = 0. (19)
We propose the calibration of the form W ?(λ) = W (αˆ, βˆ, θˆ) ◦ exp(Kλ), where exp(·) is per-
formed element-wise, ◦ denotes element-wise product, and λ is a r× 1 vector of parameters to
be estimated. The choice of this calibration function is motivated by the equivalence between
solving (19) and minimizing the convex function for λ,
1>{W (αˆ, βˆ, θˆ) ◦ exp(Kλ)} − l>λ, (20)
where 1 is an m× 1 vector of ones. The convexity of (20) ensures that the solution to (19) is
unique and can be found efficiently, particularly when the r × r Hessian matrix is used in the
estimation of λ. Specifically, the jth column of the Hessian matrix is K>{K·j ◦W (αˆ, βˆ, θˆ) ◦
exp(Kλ)}, where K·j is the jth column of K . We minimize (20) by solving (19) using the R
(R Development Core Team, 2014) package nleqslv (Hasselman, 2016).
5.3 Choice of models for deriving restrictions
In this section, we provide a discussion on how to choose the models pr(Aij | X i,j−1;βw) and
pr(Rij = 1 | H i,j−1, Ri,j−1 = 1;θw) to derive restrictions (4) and (15). Here we emphasize again
that the models for deriving the restrictions and the models for estimating the initial weights
can be different.
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First, as long as
(a) the models for deriving restrictions are parameterized such that pr(Aij | X i,j−1;βwb =
αˆ,βwd = 0) = pr(Aij | Ai,j−1; αˆ) (here pr(Aij | Ai,j−1; αˆ) are the terms in the numerator
of the initial stabilized treatment weights) and pr(Rij = 1 | H i,j−1, Ri,j−1 = 1;θw = 0) =
1/2, respectively,
(b) the models for the initial weights pr(Aij | X i,j−1;β) and pr(Rij = 1 | H i,j−1, Ri,j−1 = 1;θ)
have been correctly specified,
the choice of parametrizations for pr(Aij | X i,j−1;βw) and pr(Rij = 1 | H i,j−1, Ri,j−1 = 1;θw)
does not affect the consistency of the IPWEs. This is because the initial weights will converge
to the true weights, and they themselves satisfy the population versions of the restrictions
in (4)–(5) and (15) (see the Supplementary Material for proof). Thus λˆ will converge to 0, i.e.,
no calibration is applied, thereby maintaining the consistency of the IPWEs with the initial
weights. We recommend choosing treatment process models for deriving restrictions that can
take the values of the numerator of the initial stabilized weights, while logistic models, i.e., the
restrictions (16), will suffice for the censoring process.
Second, we distinguish between covariate histories that are predictive of E(Y
aj ,rj=1
ij ), denoted
as X
Y
i,j−1, and those that are predictive of Aij, denoted as X
A
i,j−1. Some elements of X
Y
i,j−1 and
X
A
i,j−1 overlap which leads to confounding bias, while others may be distinct from each other.
We recommend prioritizing X˜Yi,j−1, i.e., functionals of X
Y
i,j−1, for inclusion in the models of
the treatment and censoring processes for deriving restrictions at visit j. This is because,
conditional on Ai,j−1, it is precisely X
Y
i,j−1 that induces confounding bias, as they confound
the effect of aj on E(Y
aj ,rj=1
ij | Ai,j−1, Ri,j−1 = 1). X
Y
i,j−1 also induces selection bias if their
distribution changes when conditioning on being uncensored.
Our recommendation is partly supported by the fact that the left-hand side of (18) is
equivalent to the augmentation term in the augmented inverse probability weighted estimator
(AIPWE) for estimating E(YiT ) in the presence of censoring (Robins et al., 1995; Robins and
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Rotnitzky, 1995; Rotnitzky and Robins, 1995) if H˜i,j−1 is replaced by an estimate of E(YiT |
X
Y
i,j−1). In particular, if the estimate of E(YiT |XYi,j−1) is linear in X˜Yi,j−1, and H˜i,j−1 contains
X˜Yi,j−1, then our estimator based on the calibrated weights can exploit the same information
in the observed data as the AIPWE. This is because the augmentation term based on our
calibrated weights will be zero by definition of the restrictions. Furthermore, for estimating
the average treatment effect in the cross-sectional setting, Zhao and Percival (2017) find that
balancing all pre-treatment covariates in the outcome model is more efficient than balancing
only pre-treatment covariates in the treatment model when constructing covariate balancing
weights for IPTW.
6 Simulation study
We conduct a simulation study to assess the finite sample performance of the IPWE for MSMs
based on our calibrated estimation approach and the maximum likelihood approach for weight
estimation.
6.1 Design
The design of the simulation studies is motivated by the HERS data, where the time-varying
treatment is an ordinal variable. The data generating mechanism for a patient is summarized
in Table 1 and Figure 1 provides a pictorial description. We omit the subscript i for patients
for clearer presentation.
A1 AT−1 XT−1 AT
RT
XT
YT
. . .
Figure 1: The relationship between the variables in the simulation set-up.
In this set-up there are four time-varying confounders {Xj−1,1, Xj−1,2, Xj−1,3, Xj−1,4} (j =
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Table 1: Data generating mechanism for the simulations
Baseline (j = 0)
Censoring : R0 = 1
Treatment : A00 ∼ Bernoulli(0.5),
A10 | A00 = 1 ∼ Bernoulli(0.5)
Covariates: X01 = U0Z01,
X02 = U0Z02,
X03 = Z03 + 0.5(A
0
0 + A
1
0),
X04 = Z04 + 0.5(A
1
0 + A
1
0),
where U0 = 1− 0.3(A00 + A10), Z01, Z02, Z03, Z04 i.i.d∼ N(0, 1)
Follow-up visits (j = 1, . . . , 10)
Censoring : Rj | Rj−1 = 1 ∼ Bernoulli(qj)
Scenario (1): qj = 1 (no censoring)
Scenario (2): logit (qj) = 1 + A
0
j−1 + A
1
j−1 + 0.5Xj−1,1 + 0.5Xj−1,2
+ 0.2Xj−1,3 + 0.2Xj−1,4
Treatment : A0j ∼ Bernoulli(pj),
A1j | A0j = 1 ∼ Bernoulli(pj)
logit (pj) = A
0
j−1 + A
1
j−1 + 0.5Xj−1,1 + 0.5Xj−1,2 − 0.2Xj−1,3 − 0.2Xj−1,4
Covariates: Xj1 = UjZj1,
Xj2 = UjZj2,
Xj3 = Zj3 + 0.5
∑j
t=0(A
0
t + A
1
t ),
Xj4 = Zj4 + 0.5
∑j
t=0(A
0
t + A
1
t ),
where Uj = 1− 0.3(A0j + A1j), Zj1, Zj2, Zj3, Zj4 i.i.d∼ N(0, 1)
Outcome: Yj = 200 + 5(A
0
j + A
1
j +
∑j
t=j−1
∑4
l=1Xtl) + j, j ∼ N(0, 20)
1, . . . , 10), which affect the treatment assignment {A0j , A1j} and the mean of the outcome E(Yj)
at visit j. In addition, the variances of {Xj−1,1, Xj−1,2} and the means of {Xj−1,3, Xj−1,4}
are affected by treatment history Aj−1. Time-varying confounding arises from {Xj−1,3, Xj−1,4}
because conditioning on them via regression adjustment blocks the effect of previous treatments
(i.e.,
∑j−1
t=0(A
0
t + A
1
t )) through themselves.
For the censoring process, we specify two scenarios. In Scenario (1), no censoring occurs
as pr(Rj | Rj−1 = 1) = 1. In Scenario (2), covariate-dependent censoring occurs and selection
bias is induced because E(Yj) depends on Xj−1,l and E(Xj−1,l | Aj−1, Rj = 1) 6= E(Xj−1,l|Aj−1)
(l = 1, . . . , 4).
We assume a MSM E(Y
aj
j ) = γ0 + γ1
∑j
t=0(a
0
t − a1t ) + γ2
∑j
t=0 a
1
t , where a
0
t and a
1
t are
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potential values of treatment indicators A0t and A
1
t . The true treatment effects can be derived
by noting that E(Yj|Aj) = 200 + 10
∑j
t=0(A
0
t + A
1
t ), and thus γ1 = 10 and γ2 = 20.
Data from each patient are generated independently. We simulate 2500 data sets with 500,
1000 and 2500 patients and 10 scheduled follow-up visits after baseline. For weight estimation,
we assume the logistic models (6) for the treatment indicators and the logistic model for the
censoring process as in Section 4.2. We apply both the maximum likelihood approach and the
proposed calibrated estimation approach by imposing the restrictions in (5), (7) and (17) on
the initial weights obtained by maximum likelihood. Then we apply IPTW for Scenario (1) and
IPTCW for Scenario (2) with the estimated weights and use the estimating equations in (1) to
estimate γ1 and γ2.
In Scenario 1, we include an intercept and the main effects of {A0j−1, A1j−1} in the lo-
gistic models for the numerator of the stabilized treatment weights at visit j. For the de-
nominator, we additionally include the main effects of {Xj−1,1, Xj−1,2, Xj−1,3, Xj−1,4} to en-
sure that the treatment assignment models are correctly specified. In Scenario 2, we use the
same treatment assignment models as Scenario 1, and include visit-specific indicators and
the main effects of {A0j−1, A1j−1, Xj−1,1, Xj−1,2, Xj−1,3, Xj−1,4} in the censoring model at visit
j. The visit-specific intercepts were included to impose analogous restrictions to (5) in Sce-
nario 2. To consider a functional form misspecification, we use a set of transformed covari-
ates {X tj−1,1, X tj−1,2, X tj−1,3, X tj−1,4} of the form X tj−1,1 = (Xj−1,1)3/9, X tj−1,2 = Xj−1,1Xj−1,2,
X tj−1,3 = log(|Xj−1,3|) + 4 and X tj−1,4 = exp(Xj−1,4)/{1 + exp(Xj−1,4)} in place of the cor-
rect covariates {Xj−1,1, Xj−1,2, Xj−1,3, Xj−1,4} for estimating the initial weights and for deriving
restrictions for calibration.
6.2 Results
Table 2 summarizes the results of the simulation studies. When the models for the treatment
and censoring processes are correctly specified, i.e., when the correct covariates are used, it
is not surprising that the biases from IPWEs with weights based on maximum likelihood and
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with calibrated weights are negligible and the standard deviations decrease as sample size
increases. However, the IPWEs with calibrated weights have smaller standard deviations and
mean squared errors than the IPWEs with weights from maximum likelihood because the
calibration reduces the finite-sample estimation error by optimising covariate balance.
Table 2: Empirical bias, standard deviation (SD) and root mean squared error (RMSE) of
the parameter estimates in the marginal structural model from applying inverse probability of
treatment weighting and inverse probability of treatment and censoring weighting to Scenarios
(1) and (2), respectively, in the simulation study. The weights are based on the maximum
likelihood (MLE) and calibration (CMLE) approaches.
Scenario 1 Scenario 2
Bias SD RMSE Bias SD RMSE
(γ1, γ2) (γ1, γ2) (γ1, γ2) (γ1, γ2) (γ1, γ2) (γ1, γ2)
n = 500
correct covariates
MLE −0.00 0.02 0.71 0.67 0.71 0.67 −0.02 0.00 1.19 1.01 1.19 1.01
CMLE −0.01 0.00 0.63 0.59 0.63 0.59 −0.03 −0.01 1.12 0.95 1.12 0.95
transformed covariates
MLE 0.19 0.33 1.67 1.15 1.68 1.19 0.10 0.25 2.15 1.44 2.15 1.46
CMLE 0.12 0.29 0.52 0.43 0.53 0.52 0.07 0.17 0.94 0.77 0.95 0.79
n = 1000
correct covariates
MLE 0.01 0.01 0.51 0.56 0.51 0.56 −0.02 0.00 0.99 0.81 0.99 0.81
CMLE 0.01 0.02 0.48 0.47 0.48 0.47 −0.02 −0.01 0.85 0.72 0.85 0.72
transformed covariates
MLE 0.13 0.29 1.59 1.46 1.60 1.49 0.05 0.30 1.83 1.71 1.83 1.73
CMLE 0.13 0.27 0.41 0.34 0.43 0.44 0.09 0.17 0.75 0.61 0.76 0.63
n = 2500
correct covariates
MLE −0.00 −0.01 0.34 0.40 0.34 0.40 0.02 0.00 0.69 0.63 0.69 0.63
CMLE −0.00 −0.01 0.31 0.33 0.31 0.33 0.01 −0.00 0.59 0.51 0.59 0.51
transformed covariates
MLE 0.20 0.28 2.20 2.09 2.21 2.11 0.17 0.33 2.62 2.62 2.62 2.65
CMLE 0.14 0.26 0.31 0.27 0.34 0.38 0.07 0.15 0.57 0.47 0.57 0.49
In contrast, when the models for the treatment and censoring processes are misspecified, i.e.,
when the transformed covariates are used, the IPWEs with weights from maximum likelihood
and with calibrated weights both have non-negligible biases that do not decrease with increasing
sample size, although for most of the scenarios, the IPWEs with calibrated weights have slightly
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smaller biases. However, the IPWEs with calibrated weights are more efficient with much lower
standard deviations. As a result, the IPWEs with calibrated weights have much smaller mean
squared errors than the IPWEs with weights from maximum likelihood.
A more alarming feature of the IPWEs with weights from maximum likelihood is that the
large standard deviations and mean squared errors even increase with sample size. Under
model misspecification, this occurred because a few sets of estimated weights from maximum
likelihood exacerbated the extremeness of the tails of the sampling distribution of the parameter
estimators as sample size increased. Robins et al. (2007, pp. 553–4) give more details of this
phenomenon. In contrast, the IPWEs with calibrated weights do not exhibit this undesirable
property and show more robustness to the functional form misspecification in our simulation
set-up.
Overall, the simulation results show that the proposed calibration approach can improve
the efficiency of the IPWEs for MSMs and provide more robustness to functional form misspec-
ification.
6.3 Theoretical explanations
The above empirical findings about the performance of the IPWEs with calibrated weights
can be explained by the recent theoretical results in Tan (2017). Tan (2017) shows that even
under model misspecification, calibration with restrictions on covariate balance can reduce the
relative error of the estimated weight compared to the true weights, which controls the mean
squared error of the IPWE. The maximum likelihood approach for weight estimation focuses
on reducing the absolute error of the estimated weights compared to the true weights, which
is not directly connected to the mean squared error of the IPWE. Therefore, under model
misspecification calibrating the weights in terms of covariate balance can still reduce the mean
squared error of the IPWE and improve its efficiency. However, since bias is quantified by
averaging over repeated samples, depending on specific set-up for model misspecification, the
IPWE with weights from maximum likelihood can have similar or smaller bias than the IPWE
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with calibrated weights because large positive and negative differences from the true parameter
values can be cancelled out when averaging across samples.
In the Supplementary Material, we also show why the maximum likelihood approach may
perform poorly in terms of removing covariate imbalances asymptotically under mild model
misspecification. Consequently, these covariate imbalances lead to poor performance of the
corresponding IPWE even with large sample size.
7 Application to the HERS data
7.1 Description of the cohort
At the early period of the HERS from 1993 to 1995, treatment with a single ART was recom-
mended for patients with CD4 cell counts less than 500. Beginning in late 1995 and early 1996,
HAART (a combination of three or more ARTs) became more widely used in the HERS co-
hort. This increasing use of HAART is reflected in the right panel of Figure 2, which presents
the crude percentages of patients who received HAART over the follow-up visits. Since the
enrolment period of the HERS was between 1993 and 1995, the upward trend of HAART use
started at visit 5, roughly two and half years into the study. The left panel of Figure 2 also
presents the sample averages of the CD4 counts at each visit, which show a decreasing trend
up to visit 5. Then there is a level-off which coincides with the widespread use of HAART in
this cohort. This phenomenon does not necessarily suggest the efficacy of HAART because it
could be due to selection bias from dropout of patients with severe disease progression or other
factors.
Table 3: The number of patients who were HIV-positive at enrolment and still under follow-up,
had their CD4 count observed, and dropped out at each visit in the HERS data.
Visit 1 2 3 4 5 6 7 8 9 10 11 12
In follow-up 871 815 787 748 702 668 636 614 595 571 553 449
CD4 observed 850 706 692 665 617 587 576 547 522 506 492 405
Dropped out 56 28 39 46 34 32 22 19 24 18 104 133
As mentioned, attrition by dropout in the HERS is substantial. Table 3 displays the number
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Figure 2: The average CD4 cell count and the proportion of patients who received HAART
and one or two ARTs at each visit in the HERS data.
of patients who were HIV-positive at enrolment and still under follow-up, had their CD4 count
observed, and dropped out at each visit. Besides attrition, there were secondary sources of
missing data which resulted in intermittent missing data (before being lost to follow-up), missing
data at enrolment for CD4 counts, and left-censored HIV viral load at the lower detection limit
(LDL). We deal with these by following the approaches in Ko et al. (2003). Specifically, if there
was one intermittent missing CD4 count value then the last observed value was carried forward;
otherwise the patient was treated as having dropped out between their last observed visit and
the next visit. Missing CD4 values at enrolment were imputed from the patient’s second visit,
if possible; otherwise the patients missing CD4 values at visits 1 and 2 were excluded from the
analysis. Finally, left-censored viral load values were imputed from a uniform distribution on
the interval [0,LDL], where LDL was set at either 50 (13% of the viral load observations) or
500 (1% of the viral load observations) depending on the assays used.
7.2 Model parameterizations and estimation
Since HAART was not available at enrolment in the HERS cohort, we follow Ko et al. (2003)
and treat visit 7, when HAART was more widely used in the HERS, as the ‘baseline’ and
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estimate the causal effects of HAART over the two-year period between visit 8 and visit 12.
In total, there are 610 patients at visit 7 who had at least one CD4 count measured between
visit 8 and 12 and sufficient information for covariates to estimate the weights for IPTW and
IPTCW. The total number of CD4 count observations for analysis is 2581.
As discussed in Section 1.4, in order to provide a more precise estimate of the causal effect
of HAART relative to no treatment, we treat the time-varying antiviral treatment as an ordinal
variable with 3 levels: ‘no treatment’, ‘ART other than HAART’ and ‘HAART’. Furthermore,
we stratify the treatment effects within categories of CD4 count at visit 7, which are coded as
Di = 0 if Yi7 < 200, Di = 1 if 200 ≤ Yi7 ≤ 500 and Di = 2 if Yi7 > 500, where Yi7 is the CD4
count at visit 7.
Specifically, we assume the following MSM
E(Y
aj
ij ) = δ0j +
2∑
k=1
δkI(Di = k) + δ
>
vVi +
2∑
k=0
I(Di = k)
{
γ1k
j∑
l=8
(a0l − a1l ) + γ2k
j∑
l=8
a1l
}
for j = 8, . . . , 12, where δ0j are visit-specific intercept terms, Vi are baseline covariates evalu-
ated at visit 7, and δv are their corresponding regression coefficients. For Vi, we include the
following variables at visit 7: log10 HIV viral load, HIV symptom level (5-point scale), status
of one or two ARTs and status of HAART. We also estimate an overall treatment effect by
constraining γ1k and γ2k to be constant across k for the baseline CD4 count level Di. An addi-
tional MSM for evaluating the short-term treatment effect is also considered and presented in
the Supplementary Material.
The parameters in the MSMs were estimated by applying IPTW and IPTCW, with weights
estimated by maximum likelihood and by applying the proposed calibration. For IPTW, the
treatment model (6) was used to obtain maximum likelihood estimates of the weights and
to derive restrictions (7) for calibration. For the numerator in the SIPTW, we included the
following covariates in the model for the ordinal treatment at visit j: visit indicators; status of
one or two ARTs and status of HAART at visits j − 1 and j − 2. For the denominator in the
SIPTW, we additionally included: square root of CD4 count, log10 of HIV viral load and HIV
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symptom scale at visits j − 1 and j − 2; the two-way interactions between square root of CD4
count and status of HAART, square root of CD4 count and status of one or two ARTs, log10 of
HIV viral load and status of HAART, log10 of HIV viral load and status of one or two ARTs,
square root of CD4 count and log10 of HIV viral load at visit j − 1; square root of CD4 count,
log10 of HIV viral load and status of one or two ARTs at enrolment; site indicators; and race
indicators (black, white, other).
For IPTCW, a logistic model with the same covariates as those in the treatment assignment
model was used for the censoring process to obtain maximum likelihood estimates of the inverse
probability of censoring weights and to derive restrictions (16) for their calibrated version. For
fair comparison, the maximum likelihood estimates of the weights in IPTW were scaled to
sum to the sample size available at each visit; and the weights from maximum likelihood for
IPTCW were scaled to sum to 5 times the sample size at visit 7 (i.e., the number of outcome
measurements that would have been observed had nobody been censored from visit 7 onwards).
Finally, we estimated standard errors with 2500 non-parametric bootstrap samples by treating
patients as the resampling unit.
7.3 Results
We first examine the estimated weights from maximum likelihood and the proposed calibration
approach. Before scaling, the mean of the weights from maximum likelihood for IPTW was 1.01,
and the standard deviation, the minimum and maximum of these weights were 0.65, 0.01 and
9.60, respectively. Therefore, these estimated weights do not strongly indicate nonpositivity
(Cole and Herna´n, 2008), but do suggest that confounding by observed covariates is present
in the HERS data. An analysis based on the assumption of no measured confounders, e.g.,
estimating the parameters of the MSMs with no weighting applied, is thus unlikely to be
unbiased. Overall, the empirical distributions of the weights from both maximum likelihood
and the calibration approach appear to be well-behaved. Further details can be found in the
Supplementary Material.
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Table 4 presents the estimates and standard errors of the parameters in the specified MSMs
with no weighting, IPTW and IPTCW. The results of the na¨ıve analysis with no weighting
applied, as shown in the first two rows of Table 4, strongly suggest that, compared with no
treatment, HAART was effective at increasing the CD4 counts over time for those with CD4 ≤
500 at visit 7, and one or two ARTs was effective for those with 200 ≤ CD4 ≤ 500 at visit 7.
However, point estimates for the group with CD4 > 500 at visit 7 showed detrimental effects
of both HAART and one or two ARTs.
Table 4: Parameter estimates and their standard errors of the MSMs by applying no weighting,
IPTW and IPTCW with weights from maximum likelihood (MLE) and from the calibration
approach (CMLE) to the HERS data.
Weight Cumulative Strata by CD4 cell count at visit 7 No stratification
Estimation Effect < 200 200-500 > 500
No Weighting
≤ 2 ARTs 8.57 (9.33) 13.66 (7.86) −27.36 (18.40) 0.51 (8.06)
HAART 26.34 (8.37) 27.40 (8.25) −25.59 (16.45) 14.46 (7.99)
Treatment only
MLE
≤ 2 ARTs 13.27 (9.84) 16.23 (8.71) −26.44 (23.06) 5.59 (9.58)
HAART 27.78 (9.69) 28.63 (10.24) −2.67 (23.16) 20.89 (10.04)
CMLE
≤ 2 ARTs 14.35 (9.09) 26.60 (7.60) 5.25 (18.09) 18.59 (7.23)
HAART 36.53 (8.09) 34.73 (7.88) −2.75 (17.87) 28.16 (7.36)
Treatment and dropout
MLE
≤ 2 ARTs 11.70 (9.29) 17.11 (8.57) −24.75 (22.74) 6.84 (9.07)
HAART 25.79 (9.19) 28.80 (10.49) −2.08 (22.39) 21.19 (9.72)
CMLE
≤ 2 ARTs 11.92 (8.67) 27.74 (7.66) 8.60 (17.74) 19.26 (7.08)
HAART 33.11 (7.93) 32.75 (8.00) 3.10 (16.94) 27.37 (7.24)
Applying IPTW with weights from maximum likelihood provides an upward adjustment of
the treatment effects, as seen in the third and fourth rows of Table 4. The largest adjustments
for one or two ARTs and HAART are in the CD4 < 200 and CD4 > 500 strata, respectively.
Overall, this results in a fairly substantial upward adjustment for the treatment effects in the
MSM with no stratification. However, applying IPTW also increased the standard errors of the
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estimated treatment effects.
The fifth and sixth rows in Table 4 present the results from applying IPTW with calibrated
weights. It appears that HAART had an even greater effect on increasing CD4 counts for those
with CD4 ≤ 500 at visit 7 and overall without stratification, compared with the results based on
weights from maximum likelihood. There were also substantial increases in the estimated effects
of one or two ARTs for those with ≥ 200 and overall. As anticipated, the estimated standard
errors with the calibrated weights are much smaller even compared to the na¨ıve analysis with
no weighting applied.
It is possible to gauge how well the weights from maximum likelihood adjust for confound-
ing from observed covariates, by examining the standard deviation of the estimated calibration
functions c(·, λˆ). A large non-zero value would provide evidence that substantial residual con-
founding still exists after weighting with weights from maximum likelihood. For IPTW, the
mean and standard deviation of c(·, λˆ) were 1.09 and 0.61, which suggest that a fair amount of
residual confounding from observed covariates has been addressed after applying the calibration
to the weights from maximum likelihood.
Further adjustment for selection bias due to dependent censoring appears to have largely
minor effects, as seen in the last four rows of Table 4. The most notable modifications occur
in the CD4 > 500 strata. However, there is substantial uncertainty associated with these
estimated treatment effects, therefore the evidence is insufficient to draw a conclusion.
As expected, our estimated treatment effects for HAART are generally much larger (more
than 1 standard error) than those reported in Ko et al. (2003), since we have separated the
group with one or two ARTs from the group with no treatment. The slightly larger effect of
HAART in the CD4 > 500 strata from Ko et al. (2003) is again associated with substantial
uncertainty.
In conclusion, the results in Table 4 indicate that there were clinically substantial and
statistically significant therapeutic effect of cumulative exposure to HAART for those patients
with initial CD4 count ≤ 500, which is consistent with the findings in Ko et al. (2003) and the
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recommended treatment guideline during the study period of the HERS.
8 Conclusion and discussion
In this paper we have proposed a new approach to improving efficiency and robustness of
the IPWE when addressing time-varying confounding and dependent censoring in MSMs for
longitudinal outcomes with arbitrary marginal treatment distributions. Our key idea was to
calibrate a set of initial weights from maximum likelihood by imposing covariate balancing
restrictions that imply treatment assignments are unassociated with histories of covariates and
outcomes conditional on treatment history, and the uncensored observations are a representa-
tive sample of the target population after weighting the study sample. Our method resembles
the use of calibration to improve estimation efficiency in the survey sampling literature, where
sampling weights are calibrated to make use of known population information on some auxiliary
variables (Deville and Sa¨rndal, 1992). Specifically, our method calibrates the initial weights to
make use of known properties of the true probabilities of treatment assignment and censor-
ing, in particular, their balancing score property (Rosenbaum and Rubin, 1983). Consistent
with the empirical and theoretical findings in the covariate balancing weight literature for the
cross-sectional settings, our simulations showed that in longitudinal settings the IPWE with
calibrated weights had smaller variance and mean squared error than the IPWE with weights
from maximum likelihood under correct and incorrect model specification. To the best of our
knowledge, our proposed method is the first approach to accommodating both time-varying
confounding and dependent censoring in MSMs with arbitrary marginal treatment distribu-
tions using the general idea of covariate balancing. As briefly discussed, the difficulty of using
the covariate balancing weights in longitudinal settings is that it is not obvious how to derive
the covariate balancing restrictions in order to improve the estimation of the causal treatment
effects of interest. We provided a coherent framework to derive such restrictions that were
tailored to the common scenarios in fitting MSMs using observational cohort data from clini-
cal studies such as the HERS. This will hopefully promote more widespread use of MSMs for
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various types of treatments/exposure in practice.
There are several directions for future research. First, it would be useful to incorporate
data-adaptive methods into our approach. For example, the initial weights from maximum
likelihood can be replaced with weights estimated by data-adaptive methods. This can provide
some protection from severe model misspecification (e.g., omission of higher-order moments and
interactions of the covariates), and therefore reduce the possibility of large bias for IPWEs with
calibrated weights. In addition, data-adaptive methods are also useful to identify functionals
of the covariates to be balanced according to whether they predict the outcome. Second, it is
natural to extend our method to a continuous-time censoring process. This would preclude the
need to discretize continuous censoring times. Finally, our method requires the development
of sensitivity analysis strategies to assess the impact of violations to the no unmeasured con-
founders assumption. Ko et al. (2003) implemented the sensitivity analysis approach suggested
in Robins (1999a) by introducing a sensitivity parameter defined as the difference between the
means of the potential outcomes given observed treatment/covariate histories. This approach
is relatively straightforward for binary treatments. But it is not obvious how to generalize it
to non-binary treatments. A recent alternative sensitivity analysis approach for IPWEs via
percentile bootstrap (Zhao et al., 2017) may shed some light on this problem.
Supplementary Material
Supplementary material includes further examples of the proposed restrictions, proofs in Sec-
tions 4 and 5 as well as additional analyses of the HERS data. R code for the simulation study
is available at https://github.com/seanyiu5/.
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Supplementary Material for“Joint calibrated estimation
of inverse probability of treatment and censoring weights
for marginal structural models”
Sean Yiu∗ and Li Su
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Cambridge, Cambridge, CB2 0SR, UK
1 Calibration restrictions for time-varying continuous
treatments
We demonstrate how restrictions in equation (4) of the main text can be derived for a
sequence of continuous treatments. We assume that the time-varying continuous treat-
ment at visit j for the ith patient follows a heteroscedastic normal linear model Aij ∼
N{X˜µ>i,j−1βµ, exp(X˜σ>i,j−1βσ)}, where X˜µi,j−1 and X˜σi,j−1 include 1 and functionals of X i,j−1
(e.g., interactions), and βµ and βσ are corresponding regression coefficients. Then
∂
∂βµ
log{pr(Aij | X˜µi,j−1, X˜σi,j−1;βµ,βσ)} =
(Aij − X˜µ>i,j−1βµ)
exp(X˜σ>i,j−1β
σ)
X˜µi,j−1,
∂
∂βσ
log{pr(Aij | X˜µi,j−1, X˜σi,j−1;βµ,βσ)} =
1
2
{
−1 + (Aij − X˜
µ>
i,j−1β
µ)2
exp(X˜σ>i,j−1β
σ)
}
X˜σi,j−1.
By substituting the above equations into (4) of the main text, the restrictions based on
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this normal linear model for the continuous treatments are
T∑
j=1
n∑
i=1
SWA?ij (λ)
j∑
k=1
(Aik − µˆik)
σˆ2ik
X˜µi,k−1 = 0,
T∑
j=1
n∑
i=1
SWA?ij (λ)
j∑
k=1
{
−1 + (Aik − µˆik)
2
σˆ2ik
}
X˜σi,k−1 = 0,
where µˆik and σˆ
2
ik are the estimated mean and variance of the continuous treatments from
fitting the same normal linear model but with treatment history as the only covariates.
Similarly to the ordinal treatments in the main text, these restrictions are designed to remove
the associations between the covariates (X˜µi,k−1 and X˜
σ
i,k−1) and the standardized residuals
from the treatment model for the numerator of the initial stabilized weights after weighting
the current sample.
2 Property of inverse probability of censoring weights
We show that pr∗(Ri1 | H i0) = 1/2 in Section 4.2.1 of the main text, where ∗ denotes the
pseudo-population consisting of the 1/pr(Ri1 = 1|H i0)− 1 copies of the complete cases (i.e.,
those with Ri1 = 1) and the incomplete cases (i.e., those with Ri1 = 0).
Proof. Specifically, we have
pr∗(Ri1|H i0) = Ri1{1/pr(Ri1 = 1|H i0)− 1}pr(Ri1 = 1|H i0) + (1−Ri1)pr(Ri1 = 0|H i0){1/pr(Ri1 = 1|H i0)− 1}pr(Ri1 = 1|H i0) + pr(Ri1 = 0|H i0)
=
Ri1pr(Ri1 = 0|H i0) + (1−Ri1)pr(Ri1 = 0|H i0)
2pr(Ri1 = 0|H i0)
= 1/2
2
3 Equivalence of censoring restrictions in (16) and (17)
of the main text
By writing out the terms in the summation in j, equation (16) of the main text is equal to
n∑
i=1
[
T{Ri1WC?i1 (λ)− 1}H˜i0 + (T − 1){Ri2WC?i2 (λ)−Ri1WC?i1 (λ)}H˜i1
+ . . .+ {RiTWC?iT (λ)−Ri,T−1WC?i,T−1(λ)}H˜i,T−1
]
= 0,
which follows from the fact that Ri0 = 1 for all i and by convention W
C?
i0 (λ) = 1 for all i.
Next, we bring T
∑n
i=1 H˜i0 to the right-hand side,
n∑
i=1
[
TRi1W
C?
i1 (λ)H˜i0 + (T − 1){Ri2WC?i2 (λ)−Ri1WC?i1 (λ)}H˜i1
+ . . .+ {RiTWC?iT (λ)−Ri,T−1WC?i,T−1(λ)}H˜i,T−1
]
= T
n∑
i=1
H˜i0.
Now collect the coefficients for the weights
n∑
i=1
[
Ri1W
C?
i1 (λ){T H˜i0 − (T − 1)H˜i1}+Ri2WC?i2 (λ){(T − 1)H˜i1 − (T − 2)H˜i2}
+ . . .+RiTW
C?
iT (λ)H˜i,T−1
]
= T
n∑
i=1
H˜i0.
When written in summation form, the above equation is equivalent to (17) in the main text.
4 Calibration restrictions for stabilized inverse proba-
bility of censoring weights
Similarly to inverse probability of treatment weighting, stabilized weights for censoring,
SWCij (ηˆ, θˆ) = W
C
ij (θˆ)
∏j
k=1 pi
s
ik(ηˆ), can be used, where pi
s
ik(η) = pr(Rik = 1 | Ai,k−1, Ri,k−1 =
1;η) is a parametric model for the censoring process given the treatment history only. For
completeness, we describe our proposed method for calibrating stabilized weights for censor-
ing in this section.
3
4.1 The two time period setting
The idea of stabilized weights is to create a pseudo-population that is representative of the
population that would have been observed had nobody been censored at visit 1, which we
refer to as the complete population, and where each patient in the complete population has
been weighted by pisi1(ηˆ). In other words, we down-weight patients who are unlikely to be
observed at visit 1 based solely on treatment history. Therefore the task is less ambitious
than what unstabilized weights are trying to achieve. Restrictions for the stabilized weights
can be derived, e.g., by multiplying the summands in (10) of the main text by pisi1(ηˆ),
n∑
i=1
Ri1SW
C?
i1 (λ)H˜i0 =
n∑
i=1
pisi1(ηˆ)H˜i0,
where SWC?i1 (λ) = SW
C
i1 (ηˆ, θˆ)c(H i0,λ). Note that, if the censoring model is correctly
specified, i.e., WCi1 (θˆ) converges in probability to the true censoring weight W
C
i1 as n → ∞,
and E(Ri1W
C
i1 | H i0, Ri0 = 1) = 1, then these restrictions, after scaling by n, are satisfied
asymptotically.
4.2 The general longitudinal setting
Restrictions for stabilized censoring weights in the general longitudinal setting can be derived
similarly as above. In particular, we can multiply the summand indexed by j in equation
(16) of the main text by the stabilizing factor
∏j
k=1 pi
s
ik(ηˆ),
T∑
j=1
n∑
i=1
(T − j + 1) [RijSWC?ij (λ)−Ri,j−1SWC?i,j−1(λ)pisij(ηˆ)] H˜i,j−1 = 0,
where SWC?ij (λ) = SW
C
ij (ηˆ, θˆ)c(H i,j−1,λ). These restrictions, after scaling by n, are again
satisfied asymptotically (n → ∞) without calibration if the censoring model is correctly
specified, i.e., when WCij (θˆ) converges in probability to the true censoring weight W
C
ij as
n→∞, and E(RijWCij | H i,j−1, Ri0 = 1) = 1.
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To facilitate the implementation procedure, it is more convenient to re-express these
restrictions as
T∑
j=1
n∑
i=1
RijSW
C?
ij (λ)
[
(T − j + 1)H˜i,j−1 − (T − j)pisi,j+1(ηˆ)H˜ij
]
= T
n∑
i=1
pisi1(ηˆ)H˜i0,
which can be derived by using the technique described in Section 3.
5 The impact of calibration on the true inverse prob-
ability of treatment weights
We show that the true inverse probability of treatment weights satisfy the restrictions (4)
in the main text asymptotically, so calibration will not alter these weights asymptotically.
As a result, calibration will maintain the consistency of the inverse probability of treatment
weighted estimator when the models for the initial weights are correctly specified.
Without loss of generality, suppose that Aij and X i,j−1 (j = 1, . . . , T ) are continuous.
Let SWAij (α) =
∏j
k=1 pr(Aik | Ai,k−1;α)/
∏j
k=1 pr(Aik | X i,k−1). That is, the numerator
in SWAij (α) is arbitrary and only depends on treatment history, and the denominator in
SWAij (α) is the true treatment assignment probabilities. We show that
E
[
SWAij (α)
j∑
k=1
∂
∂βw
log{pr(Aik | X i,k−1;βw)}
∣∣∣
{βwb=α,βwd=0}
]
= 0
for any model pr(Aik | X i,k−1;βw) that satisfies pr(Aik | X i,k−1;βwb = α,βwd = 0) =
pr(Aik | Ai,k−1;α).
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Proof.
E
[
SWAij (α)
j∑
k=1
∂
∂βw
log{pr(Aik | X i,k−1;βw)}
∣∣∣
{βwb=α,βwd=0}
]
=E
[
j∏
k=1
pr(Aik | Ai,k−1;α)
pr(Aik | X i,k−1)
{
∂
∂βw
log
{
j∏
k=1
pr(Aik | X i,k−1;βw)
}∣∣∣
{βwb=α,βwd=0}
}]
=E
[
j∏
k=1
1
pr(Aik | X i,k−1)
{
∂
∂βw
j∏
k=1
pr(Aik | X i,k−1;βw)
∣∣∣
{βwb=α,βwd=0}
}]
=
∫
Aij
∫
Xi,j−1
j∏
k=1
1
pr(Aik | X i,k−1)
{
∂
∂βw
j∏
k=1
pr(Aik | X i,k−1;βw)
∣∣∣
{βwb=α,βwd=0}
}
×
j∏
k=1
{
pr(Aik | X i,k−1)pr(Xi,k−1 | Ai,k−1, X i,k−2)
}
dAij dX i,j−1
=
∫
Aij
∫
Xi,j−1
{
∂
∂βw
j∏
k=1
pr(Aik | X i,k−1;βw)
∣∣∣
{βwb=α,βwd=0}
}
×
j∏
k=1
pr(Xi,k−1 | Ai,k−1, X i,k−2) dAij dX i,j−1.
Assuming that we can interchange differentiation and integration, the above expression is
equal to
∂
∂βw
{∫
Aij
∫
Xi,j−1
j∏
k=1
pr(Aik | X i,k−1;βw)pr(Xi,k−1 | Ai,k−1, X i,k−2) dAij dX i,j−1
}∣∣∣
{βwb=α,βwd=0}
=
∂
∂βw
1
∣∣∣
{βwb=α,βwd=0}
= 0.
6 Asymptotic covariate imbalances for the maximum
likelihood approach under model misspecification
In this section, we briefly discuss why the maximum likelihood approach may perform poorly
in removing asymptotic imbalances of covariate distributions even under mild model mis-
specification. For clearer exposition, we focus on the cross-sectional setting, i.e., we drop the
6
visit subscript. Following the weighting framework in Yiu and Su (2018), we can use the
following measure to assess the covariate balance in the pseudo-population after weighting,
1
n
n∑
i=1
SWAi (αˆ, βˆ)
∂
∂βw
log{pr(Ai | Xi;βw)}
∣∣∣
{βwb=αˆ,βwd=0}
,
which is equal to the zero vector if and only if covariates are balanced in the current sample.
Without loss of generality, let Ai and Xi be continuous, and α
∗ and β∗ be the probability
limits of αˆ and βˆ, then this measure is asymptotically equivalent to
E
(
SWAi (α
∗,β∗)
∂
∂βw
log{pr(Ai | Xi;βw)}
∣∣∣
{βwb=α∗,βwd=0}
)
=
∫
Xi
∫
Ai
pr(Ai;α
∗)
pr(Ai | Xi;β∗)
∂
∂βw
log{pr(Ai | Xi;βw)}
∣∣∣
{βwb=α∗,βwd=0}
pr(Ai, Xi) dAi dXi
=
∫
Xi
∫
Ai
pr(Ai | Xi)
pr(Ai | Xi;β∗)
∂
∂βw
pr(Ai | Xi;βw)
∣∣∣
{βwb=α∗,βwd=0}
pr(Xi) dAi dXi
=
∫
Xi
∫
Ai
(
pr(Ai | Xi)
pr(Ai | Xi;β∗) − 1
)
∂
∂βw
pr(Ai | Xi;βw)
∣∣∣
{βwb=α∗,βwd=0}
pr(Xi) dAi dXi,
(1)
where the last line follows from the fact that under standard regularity assumptions, i.e., we
can interchange differentiation and integration,∫
Xi
∫
Ai
∂
∂βw
pr(Ai | Xi;βw)
∣∣∣
{βwb=α∗,βwd=0}
pr(Xi) dAi dXi = 0.
From (1), it is clear that small asymptotic imbalances can be attained whenever the relative
errors of the treatment probabilities are small, i.e., |pr(Ai | Xi)/pr(Ai | Xi;β∗) − 1| ≈ 0.
Methods for estimating β that are targeted to achieving small absolute errors of the treat-
ment probabilities, i.e., |pr(Ai | Xi)−pr(Ai | Xi;β∗)| ≈ 0, under mild model misspecification,
such as least squares, are therefore not guaranteed to perform well in terms of reducing co-
variate imbalances. This is because, as mentioned in the introduction of the main text, small
absolute errors do not necessarily imply small relative errors. Unfortunately, maximum like-
lihood for weight estimation is more geared towards achieving small absolute errors through
minimizing the Kullback-Leibler divergence rather than small relative errors (Tan, 2017). As
a result, the asymptotic covariate imbalances possibly from weights by maximum likelihood
can lead to poor performance of the corresponding IPWE.
7
ll
l
ll
ll
l
l
llll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
ll
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
ll
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
lll l
ll
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
ll
l
l
l
l
l
l
l
l
l
l
l
8 9 10 11 12
0
1
5
10
15
Figure 1: Box plots of the estimated weights stratified by visit in the HERS analysis in
Section 7 of the main text. Left two white boxes: for treatment only; right two gray boxes:
for treatment and dropout; unshaded boxes: weights based on maximum likelihood; shaded
boxes: calibrated weights.
7 Additional results from the HERS analysis
Figure 1 displays boxplots of the estimated weights by visit in the HERS analysis. In all
cases, the weights appear to be fairly well behaved and no weight seems to exert undue
influence relative to the other weights, especially for weighting with treatment only, where
all weights are less than ten.
In addition to the marginal structural model specified in the main text, we also fit the
following marginal structural model
E(Y
aj
ij ) = δ0j +
2∑
k=1
δkI(Di = k) + δ
>
v Vi +
2∑
k=0
I(Di = k)
{
γ1k(a
0
j − a1j) + γ2ka1j
}
(2)
for j = 8, . . . , 12, where δ0j are visit-specific intercept terms, Vi are baseline covariates eval-
uated at visit 7, and δv are their corresponding regression coefficients, γ1k and γ2k represent
8
strata-specific causal effects of recent exposures to one or two ARTs and HAART, respec-
tively. This model quantifies the causal effect of receiving one or two ARTs and HAART
in the previous six months on the current CD4 count, and therefore reflects the short-term
treatment effects. Again, we also fit a marginal structural model without stratification by
CD4 count at visit 7 in (2) .
Table 1 presents the results from fitting model (2) with weights estimated by the ap-
proaches described in the main text. Overall, these results exhibit a similar pattern to those
reported in Table 4 of the main text, especially for the model without stratification. Applying
inverse probability of treatment weighting with weights from maximum likelihood generally
provides an upward adjustment to the estimated treatment effects when no weighting is
applied, although with the cost of losing efficiency. In contrast, the calibration approach
provides an even larger upward adjustment relative to the no weighting approach and is
also more efficient. The consequences of adjusting for dependent censoring are again largely
minor. Finally, the estimated effects of HAART are generally larger than those in Ko et al.
(2003), except for the group CD4 counts > 500 at visit 7 where there is much uncertainty.
While Ko et al. (2003) found therapeutic effects of HAART in this group with CD4 counts
> 500, our analysis suggests that this could be a result of mixing the ‘no HAART’ group and
the ‘one or two ARTs’ group, since we found that the effect of HAART only appears to be
therapeutic relative to one or two ARTs but not relative to no treatment when applying the
maximum likelihood approach. In contrast, the calibration approach suggests that HAART
is not even therapeutic relative to one or two ARTs in the group with CD4 counts > 500.
However, since treatment history is not adjusted for in the MSM, there could be unmeasured
confounding reflected in the treatment history that leads to these counter-intuitive results.
Moreover, there is substantial uncertainty associated with the point estimates. Therefore,
the evidence is not sufficient to draw a conclusion about the treatment effects for the baseline
group with CD4 counts > 500.
9
Table 1: Parameter estimates and their standard errors of the MSMs in (2) by applying
no weighting, inverse probability of treatment weighting and inverse probability of treat-
ment and censoring weighting with weights from maximum likelihood (MLE) and from the
calibration approach (CMLE) to the HERS data.
Weight Cumulative Strata by CD4 cell count at visit 7 No stratification
Estimation Effect < 200 200-500 > 500
No Weighting
≤ 2 ARTs 23.67 (24.39) 45.60 (18.22) -96.08 (43.26) -0.88 (16.78)
HAART 67.37 (24.51) 75.86 (19.94) -94.15 (46.32) 28.93 (18.27)
Treatment only
MLE
≤ 2 ARTs 42.50 (24.86) 48.40 (20.89) -62.00 (51.89) 18.42 (20.10)
HAART 80.92 (25.98) 77.53 (25.21) -33.96 (59.05) 48.85 (23.24)
CMLE
≤ 2 ARTs 25.92 (22.66) 69.53 (20.36) -22.36 (42.27) 35.91 (16.37)
HAART 81.64 (21.79) 87.17 (19.65) -38.40 (46.75) 59.07 (16.32)
Treatment and dropout
MLE
≤ 2 ARTs 38.67 (25.41) 47.90 (21.29) -67.29 (51.72) 17.36 (19.92)
HAART 79.47 (26.56) 77.27 (26.35) -36.25 (58.11) 49.25 (23.27)
CMLE
≤ 2 ARTs 25.39 (23.13) 71.23 (21.29) -22.00 (42.40) 35.64 (16.82)
HAART 82.15 (22.75) 83.95 (20.72) -27.34 (44.32) 58.71 (16.85)
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